Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Achieve Life Sciences to post earnings of ($0.24) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Up 3.5 %

Achieve Life Sciences stock opened at $4.73 on Wednesday. Achieve Life Sciences has a one year low of $3.03 and a one year high of $10.30. The business’s fifty day moving average is $4.50 and its 200 day moving average is $4.47. The company has a debt-to-equity ratio of 4.02, a current ratio of 0.82 and a quick ratio of 0.82. The stock has a market capitalization of $162.00 million, a PE ratio of -3.09 and a beta of 1.26.

Wall Street Analyst Weigh In

ACHV has been the topic of a number of research analyst reports. Lake Street Capital lowered their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th. Oppenheimer restated an “outperform” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a research note on Monday, April 1st. Finally, Jonestrading initiated coverage on Achieve Life Sciences in a research report on Wednesday, April 17th. They set a “buy” rating and a $20.00 price objective for the company.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.